COVID-19 updates, including vaccine information, for our patients and visitors Learn More


An Errant Editing Enzyme Promotes Tumor Suppressor Loss and Leukemia Propagation


January 03, 2019  |  

​Writing in the January 3 issue of Cancer Cell, researchers at University of California San Diego School of Medicine report that detection of “copy editing” by a stem cell enzyme called ADAR1, which is active in more than 20 tumor types, may provide a kind of molecular radar for early detection of malignancies and represent a new therapeutic target for preventing cancer cell resistance to chemotherapy and radiation.

breast cancer cells NIH

JThree-dimensional culture of human breast cancer cells, with DNA stained blue and a protein in the cell surface membrane stained green.
Image courtesy of the National Institutes of Health

Adenosine deaminases are a family of three enzymes encoded by the ADAR genes, which stand for adenosine deaminase acting on RNA. They regulate gene expression by modifying nucleotides within double stranded RNA molecules, serving as fundamental editors in the development of new stem cells.

The enzyme, however, is also activated in cancers as diverse as liver, breast and leukemia. A research team led by senior author Catriona Jamieson, MD, PhD, deputy director of the Sanford Stem Cell Clinical Center and deputy director of the UC San Diego Moores Cancer Center, found that the normal functions of the ADAR1 enzyme are hijacked by pre-malignant cells, leading to a cascade of molecular consequences that promote malignant transformation, dormant cancer stem cell generation and resistance to treatment.

“We were able to illuminate the abilities of ADAR1 to ‘hyper-mutate’ tumor suppressor RNAs in leukemia and, at the same time, edit the microRNA aimed at targeting the tumor suppressor RNA. This enzyme turns on cancer resistance via a domino effect on RNA instead of DNA,” said first author Qingfei Jiang, PhD, assistant project scientist in Jamieson’s lab.

Jamieson characterized RNA editing as tweaking basic genetic blueprints, not fundamentally rewriting them. Nonetheless, the results might be dramatic. “One result of detection of malignant RNA editing could be exposing dormant cancer stem cells that often escape therapies that target dividing cells, which leads to therapeutic resistance and disease relapse, and also highlight ADAR as a potentially tractable target for cancer stem cell elimination,” said Jamieson.

Co-authors include: Jane Isquith, Maria Anna Zipeto, Raymond Diep, Jessica Pham, Nathan Delos Santos, Eduardo Reynoso, Julisia Chau, Heather Leu, Elisa Lazzari, Wenxue Ma, Sheldon Morris and Frida Holm, UC San Diego and Sanford Consortium for Regenerative Medicine; Etienne Melese, Sanford Consortium and University of British Columbia;  Rongxin Fang, Ludwig Institute for Cancer Research and UC San Diego; Mark Minden, Princess Margaret Hospital, Toronto; Bing Ren, Ludwig Institute and UC San Diego and Gabriel Pineda, UC San Diego, Sanford Consortium and National University.

Funding for this research came, in part, from the National Institutes of Health (R01CA205944, R01DK114468-01, R21CA189705, 5K12GM06524, 2P30CA023100-28), the Moores Family Foundation, the Koman Family Foundation, the Strauss Family Foundation and the Sanford Stem Cell Clinical Center.

​Care at UC San Diego Health

Cancer Services

Media Contact

Scott LaFee

Share This Article

Related News

As the first designated medical center in San Diego certified to offer this type of immunotherapy, UC San Diego Health will begin treating patients this month.
Viral infections and space travel similarly trigger inflammation and the enzymes APOBEC3C and ADAR1; UC San Diego researchers are developing ways to inhibit them as a means to potentially lower cancer ...
UC San Diego study supports launch of Phase I clinical trial to test a designer DNA agent — an antisense oligonucleotide that targets a gene called IRF4 — in patients with multiple myeloma.
Researchers at University of California San Diego School of Medicine and Moores Cancer Center used CRISPR technology to identify key regulators of aggressive chronic myeloid leukemia.

Follow Us